{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T00:18:35Z","timestamp":1794701915509,"version":"4.9.1"},"reference-count":51,"publisher":null,"issue":"10","license":[{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/lib.ossn.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kardiologiia"],"abstract":"<jats:p>\n                    <jats:italic>Aim.<\/jats:italic>\n                    To evaluate the effect of inclisiran therapy on parameters of lipid metabolism in hospitalized patients with acute ischemic stroke.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Material and methods.<\/jats:italic>\n                    A prospective, observational, non-randomized study was performed. The study included 12 patients with acute ischemic stroke prescribed with a combination lipid-lowering therapy with inclisiran (284\u2008mg as a single dose). At 15 days after the start of therapy, changes in blood lipid composition were assessed. For quantitative variables, median, maximum and minimum values were determined. The significance of differences between related samples in quantitative variables was assessed using the Mann-Whitney test.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Results.<\/jats:italic>\n                    Before the start of combination lipid-lowering therapy, total cholesterol (TC) was 7.33 mmol\/l and low-density lipoprotein C (LDL-C) was 5.23\u2008mmol\/l. At 15 days after the start of inclisiran therapy, TC significantly decreased by 52.1 % and LDL-C decreased by 71.1 %. The proportion of patients who reached the LDL-C goal was 66.7 %. There were no adverse events considered by the investigators to be related with the therapy.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Conclusion.<\/jats:italic>\n                    The strategy of early administration of inclisiran (or its combination with a statin) in patients with ischemic stroke allows safe achievement of a significant reduction in LDL-C already in 15 days after the start of therapy.\n                  <\/jats:p>","DOI":"10.18087\/cardio.2023.10.n2560","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T11:02:23Z","timestamp":1700132543000},"page":"39-46","source":"Crossref","is-referenced-by-count":4,"title":["Inclisiran in patients with acute ischemic stroke: first data"],"prefix":"10.68900","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3514-8676","authenticated-orcid":true,"given":"M. S.","family":"Cherepianskii","sequence":"first","affiliation":[{"name":"Komi Republic Clinical Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. M.","family":"Ponomareva","sequence":"additional","affiliation":[{"name":"Pitirim Sorokin Syktyvkar State University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. B.","family":"Skiba","sequence":"additional","affiliation":[{"name":"Pavlov First Saint-Petersburg State Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. M.","family":"Abakarov","sequence":"additional","affiliation":[{"name":"Komi Republic Clinical Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. V.","family":"Dudayte","sequence":"additional","affiliation":[{"name":"Komi Republic Clinical Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. A.","family":"Cherepianskaia","sequence":"additional","affiliation":[{"name":"Komi Republic Clinical Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":null,"published-online":{"date-parts":[[2023,11,8]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Boytsov S.A., Shalnova S.A., Deev A.D. Cardiovascular mortality in the Russian Federation and possible mechanisms of its changes. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(8):98\u2013103. DOI: 10.17116\/jnevro201811808198","DOI":"10.17116\/jnevro201811808198"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Quinn KL, Lam GY, Walsh JF, Bh\u00e9reur A, Brown AD, Chow CW et al. Cardiovascular Considerations in the Management of People With Suspected Long COVID. Canadian Journal of Cardiology. 2023;39(6):741\u201353. DOI: 10.1016\/j.cjca.2023.04.003","DOI":"10.1016\/j.cjca.2023.04.003"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Chilazi M, Duffy EY, Thakkar A, Michos ED. COVID and Cardiovascular Disease: What We Know in 2021. Current Atherosclerosis Reports. 2021;23(7):37. DOI: 10.1007\/s11883-021-00935-2","DOI":"10.1007\/s11883-021-00935-2"},{"key":"ref4","unstructured":"Federal State Statistics Service. Health in Russia. 2019. Statistical book. -M.: Rosstat;2019. - 170p. https:\/\/www.gks.ru\/storage\/mediabank\/Zdravoohran-2019.pdf]. ISBN 978-5-89476-470-2"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Johnson CO, Nguyen M, Roth GA, Nichols E, Alam T, Abate D et al. Global, regional, and national burden of stroke, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology. 2019;18(5):439\u201358. DOI: 10.1016\/S1474-4422(19)30034-1","DOI":"10.1016\/S1474-4422(19)30034-1"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Gattringer T, Posekany A, Niederkorn K, Knoflach M, Poltrum B, Mutzenbach S et al. Predicting Early Mortality of Acute Ischemic Stroke: Score-Based Approach. Stroke. 2019;50(2):349\u201356. DOI: 10.1161\/STROKEAHA.118.022863","DOI":"10.1161\/STROKEAHA.118.022863"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Boulanger M, B\u00e9jot Y, Rothwell PM, Touz\u00e9 E. Long\u2010Term Risk of Myocardial Infarction Compared to Recurrent Stroke After Transient Ischemic Attack and Ischemic Stroke: Systematic Review and Meta\u2010Analysis. Journal of the American Heart Association. 2018;7(2):e007267. DOI: 10.1161\/JAHA.117.007267","DOI":"10.1161\/JAHA.117.007267"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Mohan KM, Wolfe CDA, Rudd AG, Heuschmann PU, Kolominsky-Rabas PL, Grieve AP. Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke. 2011;42(5):1489\u201394. DOI: 10.1161\/STROKEAHA.110.602615","DOI":"10.1161\/STROKEAHA.110.602615"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Skajaa N, Adelborg K, Horv\u00e1th-Puh\u00f3 E, Rothman KJ, Henderson VW, Thygesen LC et al. Risks of Stroke Recurrence and Mortality After First and Recurrent Strokes in Denmark: A Nationwide Registry Study. Neurology. 2021; [Online ahead of print]. DOI: 10.1212\/WNL.0000000000013118","DOI":"10.1212\/WNL.0000000000013118"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Boytsov S.A., Drapkina O.M., Shlyakhto E.V., Konradi A.O., Balanova Yu.A., Zhernakova Yu.V. et al. Epidemiology of Cardiovascular Diseases and their Risk Factors in Regions of Russian Federation (ESSE-RF) study. Ten years later. Cardiovascular Therapy and Prevention. 2021;20(5):143\u2013 52. DOI: 10.15829\/1728-8800-2021-3007","DOI":"10.15829\/1728-8800-2021-3007"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Boehme AK, Esenwa C, Elkind MSV. Stroke Risk Factors, Genetics, and Prevention. Circulation Research. 2017;120(3):472\u201395. DOI: 10.1161\/CIRCRESAHA.116.308398","DOI":"10.1161\/CIRCRESAHA.116.308398"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Paraskevas KI, Veith FJ, Eckstein H-H, Ricco J-B, Mikhailidis DP. Cholesterol, carotid artery disease and stroke: what the vascular specialist needs to know. Annals of Translational Medicine. 2020;8(19):1265. DOI: 10.21037\/atm.2020.02.176","DOI":"10.21037\/atm.2020.02.176"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association\/American Stroke Association. Stroke. 2021;52(7):e364\u2013467. DOI: 10.1161\/STR.0000000000000375","DOI":"10.1161\/STR.0000000000000375"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Sabatine MS, Wiviott SD, Im K, Murphy SA, Giugliano RP. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis. JAMA cardiology. 2018;3(9):823\u20138. DOI: 10.1001\/jamacardio.2018.2258","DOI":"10.1001\/jamacardio.2018.2258"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Ezhov M.V., Kukharchuk V.V., Sergienko I.V., Alieva A.S., Antsiferov M.B., Ansheles A.A. et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):250\u2013 97. DOI: 10.15829\/1560-4071-2023-5471","DOI":"10.15829\/1560-4071-2023-5471"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Ray KK, Reeskamp LF, Laufs U, Banach M, Mach F, Tokg\u00f6zo\u011flu LS et al. Combination lipid-lowering therapy as first-line strategy in very high-risk patients. European Heart Journal. 2022;43(8):830\u20133. DOI: 10.1093\/eurheartj\/ehab718","DOI":"10.1093\/eurheartj\/ehab718"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Cupido AJ, Kastelein JJP. Inclisiran for the treatment of hypercholesterolaemia: implications and unanswered questions from the ORION trials. Cardiovascular Research. 2020;116(11):e136\u20139. DOI: 10.1093\/cvr\/cvaa212","DOI":"10.1093\/cvr\/cvaa212"},{"key":"ref18","unstructured":"Ischemic stroke and transient ischemic attack in adults. Clinical recommendations. 2022. Av. at: https:\/\/evidence-neurology.ru\/content\/downloadfiles\/13\/kr-po-ii-i-tia_2022_finalnii-v_ru_1650370148.pdf. https:\/\/evidence-neurology.ru\/content\/downloadfiles\/13\/kr-po-ii-i-tia_2022_finalnii-v_ ru_1650370148.pdf]"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. New England Journal of Medicine. 2020;382(16):1507\u201319. DOI: 10.1056\/NEJMoa1912387","DOI":"10.1056\/NEJMoa1912387"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Boytsov S.A., Piradov M.A., Tanashyan M.M., Voznyuk I.A., Yezhov M.V., Oshchepkova E.V. et al. Topical issues of adequate control of dyslipidemia in the prevention of acute and recurrent cerebral circulatory disorders of ischemic type. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(5):7\u201310. DOI: 10.17116\/jnevro20221220517","DOI":"10.17116\/jnevro20221220517"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Ay H, Benner T, Murat Arsava E, Furie KL, Singhal AB, Jensen MB et al. A Computerized Algorithm for Etiologic Classification of Ischemic Stroke: The Causative Classification of Stroke System. Stroke. 2007;38(11):2979\u201384. DOI: 10.1161\/STROKEAHA.107.490896","DOI":"10.1161\/STROKEAHA.107.490896"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Luo Z, Huang Z, Sun F, Guo F, Wang Y, Kao S et al. The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia. Journal of Clinical Lipidology. 2023;17(3):392\u2013400. DOI: 10.1016\/j.jacl.2023.04.010","DOI":"10.1016\/j.jacl.2023.04.010"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Medvedeva E.A., Grigorenko E.A., Mitkovskaya N.P. Innovative lipidlowering therapy: experience of inclisiran use in the Republic of Belarus. Russian Journal of Cardiology. 2023;28(4):53\u201361. DOI: 10.15829\/1560-4071-2023-5417","DOI":"10.15829\/1560-4071-2023-5417"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Ueberdiek L, Jehn U, Pavenst\u00e4dt H, Gebauer K, Reuter S. Novel Therapeutic Strategies for Dyslipidemia: First Report of Inclisiran Therapy in a Kidney Transplanted Patient. Transplant International. 2023;36:11104. DOI: 10.3389\/ti.2023.11104","DOI":"10.3389\/ti.2023.11104"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M et al. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. New England Journal of Medicine. 2017;376(15):1430\u201340. DOI: 10.1056\/NEJMoa1615758","DOI":"10.1056\/NEJMoa1615758"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Shafqat S, Arif H, Aijaz B, Islam M, Aftab U, Kumar S. Drug compliance after stroke and myocardial infarction: A comparative study. Neurology India. 2007;55(2):130\u20135. DOI: 10.4103\/0028-3886.32783","DOI":"10.4103\/0028-3886.32783"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Rajahthurai SD, Farrukh MJ, Makmor-Bakry M, Tan HJ, Fatokun O, Mohd Saffian S et al. Use of Complementary and Alternative Medicine and Adherence to Medication Therapy Among Stroke Patients: A Meta-analysis and Systematic Review. Frontiers in Pharmacology. 2022;13:870641. DOI: 10.3389\/fphar.2022.870641","DOI":"10.3389\/fphar.2022.870641"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Krasenbaum LJ, Pedarla VL, Thompson SF, Tangirala K, Cohen JM, Driessen MT. A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States. The Journal of Headache and Pain. 2022;23(1):54. DOI: 10.1186\/s10194-022-01413-z","DOI":"10.1186\/s10194-022-01413-z"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Spence JD, Viscoli CM, Inzucchi SE, Dearborn-Tomazos J, Ford GA, Gorman M et al. Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial. JAMA Neurology. 2019;76(5):526\u201335. DOI: 10.1001\/jamaneurol.2019.0079","DOI":"10.1001\/jamaneurol.2019.0079"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M et al. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. New England Journal of Medicine. 2016;374(14):1321\u201331. DOI: 10.1056\/NEJMoa1506930","DOI":"10.1056\/NEJMoa1506930"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Yang Y, Shi Y-Z, Zhang N, Wang S, Ungvari GS, Ng CH et al. The Disability Rate of 5-Year Post-Stroke and Its Correlation Factors: A National Survey in China. PLOS ONE. 2016;11(11):e0165341. DOI: 10.1371\/journal.pone.0165341","DOI":"10.1371\/journal.pone.0165341"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Banda KJ, Chu H, Kang XL, Liu D, Pien L-C, Jen H-J et al. Prevalence of dysphagia and risk of pneumonia and mortality in acute stroke patients: a meta-analysis. BMC Geriatrics. 2022;22(1):420. DOI: 10.1186\/s12877-022-02960-5","DOI":"10.1186\/s12877-022-02960-5"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Al AlShaikh S, Quinn T, Dunn W, Walters M, Dawson J. Predictive factors of non-adherence to secondary preventative medication after stroke or transient ischaemic attack: A systematic review and meta-analyses. European Stroke Journal. 2016;1(2):65\u201375. DOI: 10.1177\/2396987316647187","DOI":"10.1177\/2396987316647187"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G et al. EUWide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. European Journal of Preventive Cardiology. 2021;28(11):1279\u201389. DOI: 10.1093\/eurjpc\/zwaa047","DOI":"10.1093\/eurjpc\/zwaa047"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal. 2020;41(1):111\u201388. DOI: 10.1093\/eurheartj\/ehz455","DOI":"10.1093\/eurheartj\/ehz455"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Ray KK, Haq I, Bilitou A, Manu MC, Burden A, Aguiar C et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. The Lancet Regional Health - Europe. 2023;29:100624. DOI: 10.1016\/j.lanepe.2023.100624","DOI":"10.1016\/j.lanepe.2023.100624"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Yanishevskiy S.N., Skiba Ya.B., Polushin A.Yu. Statins in patients with acute ischemic stroke: when we should start therapy? Arterial Hypertension. 2021;27(1):16\u201328. DOI: 10.18705\/1607-419X-2021-27-1-16-28","DOI":"10.18705\/1607-419X-2021-27-1-16-28"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Catapano AL, De Caterina R, Jukema JW, Klempfner R, Landmesser U, Schiele F et al. Addressing current challenges in optimization of lipid management following an ACS event: Outcomes of the ACS EuroPath III initiative. Clinical Cardiology. 2023;46(4):407\u201315. DOI: 10.1002\/clc.23988","DOI":"10.1002\/clc.23988"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Li S, Peng Y, Wang X, Qian Y, Xiang P, Wade SW et al. Cardiovascular events and death after myocardial infarction or ischemic stroke in an older Medicare population. Clinical Cardiology. 2019;42(3):391\u20139. DOI: 10.1002\/clc.23160","DOI":"10.1002\/clc.23160"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326(7404):1423. DOI: 10.1136\/bmj.326.7404.1423","DOI":"10.1136\/bmj.326.7404.1423"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Ostwald DA, Schmitt M, Peristeris P, Gerritzen T, Durand A. The Societal Impact of Inclisiran in England: Evidence From a Population Health Approach. Value in Health. 2023;26(9):1353\u201362. DOI: 10.1016\/j.jval.2023.05.002","DOI":"10.1016\/j.jval.2023.05.002"},{"key":"ref42","unstructured":"What\u2019s new in clinical guideline Ministry of Health RF \u2018Disorders of lipid metabolism 2023\u2019. Av. at: https:\/\/scardio.ru\/content\/activities\/2023\/11042023.pdf."},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine. 2017;376(18):1713\u2013 22. DOI: 10.1056\/NEJMoa1615664","DOI":"10.1056\/NEJMoa1615664"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Kiyosue A, Honarpour N, Kurtz C, Xue A, Wasserman SM, Hirayama A. A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk. The American Journal of Cardiology. 2016;117(1):40\u20137. DOI: 10.1016\/j.amjcard.2015.10.021","DOI":"10.1016\/j.amjcard.2015.10.021"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Ray KK, Ginsberg HN, Davidson MH, Pordy R, Bessac L, Minini P et al. Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control. Circulation. 2016;134(24):1931\u201343. DOI: 10.1161\/CIRCULATIONAHA.116.024604","DOI":"10.1161\/CIRCULATIONAHA.116.024604"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Ray KK, Troquay RPT, Visseren FLJ, Leiter LA, Scott Wright R, Vikarunnessa S et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. The Lancet Diabetes & Endocrinology. 2023;11(2):109\u201319. DOI: 10.1016\/S2213-8587(22)00353-9","DOI":"10.1016\/S2213-8587(22)00353-9"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Koenig W, Ray KK, Landmesser U, Leiter LA, Schwartz GG, Wright RS et al. Efficacy and safety of inclisiran in patients with cerebrovascular disease: ORION-9, ORION-10, and ORION-11. American Journal of Preventive Cardiology. 2023;14:100503. DOI: 10.1016\/j.ajpc.2023.100503","DOI":"10.1016\/j.ajpc.2023.100503"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Katsiki N, Vrablik M, Banach M, Gouni-Berthold I. Inclisiran, LowDensity Lipoprotein Cholesterol and Lipoprotein (a). Pharmaceuticals. 2023;16(4):577. DOI: 10.3390\/ph16040577","DOI":"10.3390\/ph16040577"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Pan Y, Li H, Wang Y, Meng X, Wang Y. Causal Effect of Lp(a) [Lipoprotein(a)] Level on Ischemic Stroke and Alzheimer Disease: A Mendelian Randomization Study. Stroke. 2019;50(12):3532\u20139. DOI: 10.1161\/ STROKEAHA.119.026872","DOI":"10.1161\/STROKEAHA.119.026872"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Nambi V, Agha A. Inclisiran: A Game Changer in a Changing Game? Journal of the American College of Cardiology. 2021;77(9):1194\u20136. DOI: 10.1016\/j. jacc.2021.01.008","DOI":"10.1016\/j.jacc.2021.01.008"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Tanashyan M.M., Shamalov N.A., Voznyuk I.A., Yanishevsky S.N., Vinogradov O.I., Khasanova D.R. et al. Control of dyslipidemia in the prevention of recurrent ischemic cerebrovascular accidents (expert opinion). Neurology, Neuropsychiatry, Psychosomatics. 2022;14(4):108\u201313. DOI: 10.14412\/2074-2711-2022-4-108-113","DOI":"10.14412\/2074-2711-2022-4-108-113"}],"container-title":["Kardiologiia"],"original-title":[],"link":[{"URL":"https:\/\/lib.ossn.ru\/jour\/article\/viewFile\/2560\/1452","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:16:31Z","timestamp":1793639791000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardio.elpub.ru\/jour\/article\/view\/2560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,8]]},"references-count":51,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,11,10]]}},"URL":"https:\/\/doi.org\/10.18087\/cardio.2023.10.n2560","relation":{},"ISSN":["2412-5660","0022-9040"],"issn-type":[{"value":"2412-5660","type":"electronic"},{"value":"0022-9040","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,8]]}}}